Study wrapper · #943
Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.
Takrori E, Peshin S, Singal S Medicina (Kaunas, Lithuania). 2025.
DOI: 10.3390/medicina61111987PubMed: 41303824
Editor's note
This review synthesizes twelve studies on gastrointestinal tolerability of anti-obesity drugs in non-diabetic adults, finding nausea, vomiting, diarrhea, and constipation most common with GLP-1 agonists during dose escalation. Symptoms were generally mild to moderate but can affect adherence. The authors note heterogeneity in study design as a limitation.
Plain-language abstract
A systematic review of twelve studies found that gastrointestinal side effects such as nausea, vomiting, and diarrhea are common with anti-obesity medications, particularly GLP-1 receptor agonists.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026